Can a TB drug help smokers kick the habit with E-Cigs?
NCT ID NCT05994703
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a medication called d-cycloserine, combined with using a Juul e-cigarette, helps smokers switch completely from regular cigarettes. Twenty-five adult smokers who wanted to switch took d-cycloserine daily for six weeks and used Juul as much as they liked. The goal was to see if this approach could speed up learning new habits and reduce smoking.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- d-cycloserine (a medication) and Juul e-cigarette
- What this could lead to
- If it works, this could point toward a new way to help smokers switch to e-cigarettes and reduce harm from smoking.
- What could go wrong
- This is a very small, early Phase 2 trial with only 25 people. The results may not apply to everyone, and d-cycloserine can cause side effects like dizziness or drowsiness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
25 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Has signed the informed consent form (ICF) and is able to understand the information provided in the ICF. 2. Is 22 to 65 years of age (inclusive) at screening. 3. Smokes ≥ 10 commercially available CCs per day (no brand restrictions), for the last 12 months. 4. Expired air CO reading of at least 10 ppm as assessed at the screening session. 5. Interested in switching to an electronic cigarette. 6. Willing and able to comply with the requirements of the study. 7. Owns a smart phone with text message and data capabilities compatible with necessary surveys. Exclusion Criteria: 1. Is unhealthy or cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason) as judged by the Investigator or designated medical staff based on all available assessments from the screening period (e.g., safety laboratory, vital signs, physical examination, ECG, concomitant medications and medical history). 2. Patient Health Questionnaire (PHQ-9) score greater than 9, or a score greater than 0 on item #9 ("Thoughts that you would be better off dead, or of hurting yourself in some way") at screening. 3. Planned use of an FDA-approved smoking cessation product during the study. 4. High Blood Pressure (systolic \>150 mm Hg, diastolic \>95 mm Hg) at screening. 5. Body mass index (BMI) less than 15.0 kg/m2 or greater than 40.0 kg/m2. 6. Coronary heart disease, structural cardiac disease (including, but not limited to valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac chest pain, or history of heart attack or heart failure. 7. Has received psychotherapy or behavioral treatments within 30 days of screening, or during the study. 8. Taking antidepressants or psychoactive medications (e.g., antipsychotics, antidepressants, benzodiazepines, hypnotics). 9. Use of any of these products in the past 30 days: 1. Illegal drugs (or if the urine drug screen is positive for cocaine, tetrahydrocannabinol (THC), amphetamines, methamphetamines, or opiates); 2. Experimental (investigational) drugs that are unknown to participant; 3. Chronic opiate use; 4. Medications to treat tuberculosis (e.g., isoniazid, ethionamide). 10. Use of smokeless tobacco (chewing tobacco, snuff), cigars (except for "Black \& Mild" cigars or Cigarillos), pipes, hookah, e-cigarettes, nicotine replacement therapy or other smoking cessation treatments within 14 days of screening. 11. Pregnant or nursing (by self-report) or positive pregnancy test.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Harm reduction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rose Research Center
Charlotte, North Carolina, 28262, United States
-
Rose Research Center
Raleigh, North Carolina, 27617, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Texts and wearables team up to help latinos quit smoking and get moving
- Can an AI chatbot help cancer patients kick the habit?
- Does the clock matter? scientists randomize when Quit-Smoking chatbots ping you
- Can a WhatsApp message help smokers quit?
- Practice quitting: a new way to help smokers who Aren't ready to stop?
- Can a Quit-Smoking program built for transgender adults help them stop?